Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2005 in Combination Therapy for Relapsed/Refractory Mantle Cell Lymphoma
NCT07697339Phase 1Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Jul 2026
- Primary completion
- Aug 2027
01
Overview
Phase 1, randomised, open-label trial of HDM2005 in mantle cell lymphoma (MCL) (4 arms), sponsored by Huadong Medicine. Primary endpoints: Incidence and severity of adverse events at 12 months, Objective response rate at 11 months and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HDM2005
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07697339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697339.